Detail akcie Gyre Therap Rg online

Business Summary: Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Gyre Therapeutics Inc revenues increased 2% to $79.4M. Net income decreased 45% to $6.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Fair Value Adjustments on Other Ass decrease of 65% to $2.4M (income), stock-based compensation expense increase from $264K to $2.4M (expense).